Sign inJoin waitlistJoin the waitlist

Matthew Kutny

Director, Leukemia, Lymphoma and Histiocytosis Program · University of Alabama Hospital

Credentials: · · · · ·

History

University of Alabama Hospital
Present

Pediatric Hematology-Oncology
University of Washington-Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital
2008–2009
Pediatrics
Vanderbilt University Children’s Hospital
2005–2008
Vanderbilt University School of Medicine
2001–2005

Research

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group
Pediatric Blood & Cancer · 2011 · 98 citations
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial
JAMA Oncology · 2022 · First of 16 authors · 81 citations
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III…
Journal of Clinical Oncology · 2017 · First of 11 authors · 73 citations

Soheil Meshinchi
11 papers · 2 as a fellow
Alan Gamis
8 papers
JF
James Feusner
8 papers
EK
Edward Kolb
6 papers
JG
John Gregory
6 papers
Jessica Pollard
5 papers
Richard Aplenc
5 papers
Todd Cooper
5 papers
Aman Wadhwa
3 papers
Ana Xavier
3 papers
Bayard Powell
3 papers
Cheryl Willman
3 papers

Clinical trials

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Principal investigator · Withdrawn · Phase 1, Phase 2
Children's Oncology Group
2023
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Principal investigator · Active not recruiting · Phase 3
Children's Oncology Group
2015–2029
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030